1
|
Dunne A, Mielke LA, Allen AC, Sutton CE, Higgs R, Cunningham CC, Higgins SC, Mills KHG. A novel TLR2 agonist from Bordetella pertussis is a potent adjuvant that promotes protective immunity with an acellular pertussis vaccine. Mucosal Immunol 2015; 8:607-17. [PMID: 25315966 DOI: 10.1038/mi.2014.93] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2014] [Accepted: 09/09/2014] [Indexed: 02/04/2023]
Abstract
Bordetella pertussis causes whooping cough, a severe and often lethal respiratory infection in infants. A recent resurgence of pertussis has been linked with waning or suboptimal immunity induced with acellular pertussis vaccines (Pa) that were introduced to most developed countries in the 1990s because of safety concerns around the use of whole-cell pertussis vaccines (Pw). Pa are composed of individual B. pertussis antigens absorbed to alum and promote strong antibody, T helper type 2 (Th2) and Th17 responses, but are less effective at inducing cellular immunity mediated by Th1 cells. In contrast, Pw, which include endogenous Toll-like receptor (TLR) agonists, induce Th1 as well as Th17 responses. Here we report the identification and characterization of novel TLR2-activating lipoproteins from B. pertussis. These proteins contain a characteristic N-terminal signal peptide that is unique to Gram-negative bacteria and we demonstrate that one of these lipoproteins, BP1569, activates murine dendritic cells and macrophages and human mononuclear cells via TLR2. Furthermore, we demonstrated that a corresponding synthetic lipopeptide LP1569 has potent immunostimulatory and adjuvant properties, capable of enhancing Th1, Th17, and IgG2a antibody responses induced in mice with an experimental Pa that conferred superior protection against B. pertussis infection than an equivalent vaccine formulated with alum.
Collapse
Affiliation(s)
- A Dunne
- Molecular Immunology Group, School of Biochemistry and Immunology and Immunology Research Centre, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
| | - L A Mielke
- Immune Regulation Research Group, School of Biochemistry and Immunology and Immunology Research Centre, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
| | - A C Allen
- Immune Regulation Research Group, School of Biochemistry and Immunology and Immunology Research Centre, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
| | - C E Sutton
- Immune Regulation Research Group, School of Biochemistry and Immunology and Immunology Research Centre, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
| | - R Higgs
- Immune Regulation Research Group, School of Biochemistry and Immunology and Immunology Research Centre, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
| | - C C Cunningham
- Molecular Immunology Group, School of Biochemistry and Immunology and Immunology Research Centre, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
| | - S C Higgins
- Immune Regulation Research Group, School of Biochemistry and Immunology and Immunology Research Centre, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
| | - K H G Mills
- Immune Regulation Research Group, School of Biochemistry and Immunology and Immunology Research Centre, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland
| |
Collapse
|
2
|
Lapolla A, McBurney RD, Sutton CE, Nash LR. A clinical report on the use of Indoklon. Dis Nerv Syst 1965; 26:735-8. [PMID: 5843019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|